PACB Pacific Biosciences of California
- 1.720
- +0.040+2.38%
- 1.750
- +0.030+1.74%
Pacific Biosciences of California News
Pacific Biosciences of California Files to Sell 10.55M Shares of Common Stock for Holders
Pacific Biosciences of California | 10-Q: Quarterly report
Pacific Biosciences (PACB.US): The 2024 Q1 financial report achieved revenue of US$38.81 million, with a previous value of US$38.9 million, with an expected value of US$42.96 million; earnings per share were -0.26 dollars, the previous value was -0.31 dol
Pacific Biosciences (PACB.US): The 2024 Q1 financial report achieved revenue of US$38.81 million, with a previous value of US$38.9 million, with an expected value of US$42.96 million; earnings per share were -0.26 dollars, the previous value was -0.31 dollars, and the expected value was -0.27 dollars.
PacBio Expects To Reduce Non-GAAP Annualized Expense Run Rate By More Than $75M By End Of 2024 Vs. Initial Guidance Of 5% Growth In 2024 Operating Expenses
Initiated activities to reduce annualized run-rate operating expenses and the Company expects to achieve above the high end of previously provided range of non-GAAP reduction of $50 million to $75 mil
Earnings Flash (PACB) PACIFIC BIOSCIENCES OF CALIFORNIA Reports Q1 Revenue $38.8M
04:25 PM EDT, 05/09/2024 (MT Newswires) -- Earnings Flash (PACB) PACIFIC BIOSCIENCES OF CALIFORNIA Reports Q1 Revenue $38.8M
Pacific Biosciences Q1 2024 Adj EPS $(0.26) Beats $(0.28) Estimate, Sales $38.810M Miss $42.962M Estimate
Pacific Biosciences (NASDAQ:PACB) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.28) by 7.14 percent. This is a 16.13 percent increase over losses of $
Pacific Biosciences 1Q Loss $78.2M >PACB
Pacific Biosciences 1Q Loss $78.2M >PACB
Why Perficient Shares Are Trading Higher By Around 53%? Here Are 20 Stocks Moving In Monday's Mid-Day Session
Shares of Perficient, Inc (NASDAQ:PRFT) shares rose sharply during Monday's session after the company disclosed an acquisition deal and first-quarter FY24 results.The company stated that it has entere
Investors Heavily Search Pacific Biosciences of California, Inc. (PACB): Here Is What You Need to Know
Tesla, Deciphera Pharmaceuticals, Heartland Financial And Other Big Stocks Moving Higher On Monday
U.S. stocks were higher, with the Nasdaq Composite jumping over 50 points on Monday.Shares of Tesla, Inc. (NASDAQ:TSLA) rose sharply during Monday's session on reports the company will partner with Ba
Skechers Reports Upbeat Earnings, Joins Tutor Perini, AppFolio, Newell Brands And Other Big Stocks Moving Higher On Friday
U.S. stocks were higher, with the Dow Jones jumping over 150 points on Friday.Shares of Skechers U.S.A., Inc. (NYSE:SKX) rose sharply during Friday's session after the company reported better-than-exp
PacBio Moved to Neutral at JPMorgan After Guidance Cut
JP Morgan Downgrades Pacific Biosciences to Neutral
JP Morgan analyst Rachel Vatnsdal downgrades Pacific Biosciences from Overweight to Neutral.
Pacific Biosciences Is Maintained at Neutral by Goldman Sachs
Pacific Biosciences Is Maintained at Neutral by Goldman Sachs
Goldman Sachs: Maintains Pacific Biosciences (PACB.US) rating, adjusted from neutral to neutral, and adjusted the target price from $7.00 to $2.50.
Goldman Sachs: Maintains Pacific Biosciences (PACB.US) rating, adjusted from neutral to neutral, and adjusted the target price from $7.00 to $2.50.
Goldman Sachs Maintains Neutral on Pacific Biosciences, Lowers Price Target to $2.5
Goldman Sachs analyst Matthew Sykes maintains Pacific Biosciences (NASDAQ:PACB) with a Neutral and lowers the price target from $7 to $2.5.
Pacific Biosciences Price Target Cut to $2.50/Share From $7.00 by Goldman Sachs
Pacific Biosciences Price Target Cut to $2.50/Share From $7.00 by Goldman Sachs
PacBio Cut to Neutral at Goldman Sachs After Guidance Cut
Pacific Biosciences Is Maintained at Sector Outperform by Scotiabank
Pacific Biosciences Is Maintained at Sector Outperform by Scotiabank
Scotiabank: Maintaining the Pacific Biosciences (PACB.US) rating, adjusted from outperforming the market to outperforming the market rating, and the target price was adjusted from $15.00 to $8.00.
Scotiabank: Maintaining the Pacific Biosciences (PACB.US) rating, adjusted from outperforming the market to outperforming the market rating, and the target price was adjusted from $15.00 to $8.00.
Analysis
Price Target
No Data
